Komori
Results4883Modalis Therapeutics CorporationPharmaceuticals

Q3 Financial Results for the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated)

Cumulative operating loss for the first 3 quarters changed from ¥1,815 million in the same period of the previous year to ¥1,686 million, while net loss for the quarter attributable to owners of the parent changed from ¥1,801 million to ¥1,608 million. Business revenue was "-", and the full-year earnings forecast has not been disclosed because it is considered difficult to reasonably calculate.

Worth reading
42Recurring
Scored from 5 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
128.694
¥ million (reduction in operating loss)
Wording
Avoiding a definitive answer
How definitive the wording is.

Results for this period

Third quarter1 January 2026 to 30 September 2026ConsolidatedJapanese GAAP
Operating profit-1,686¥ million
Ordinary income-1,650¥ million
Net income attributable to owners of the parent-1,608¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.

Net income per share(¥16.59)
Financial position at period-end
Total assets2,459¥ million
of which net assets 2,317 ¥ millionEquity ratio 91.9%vs. prior year-end -1.1pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Outlook and shareholder returns
Annual Dividend Forecast¥0 → ¥0(0.0%)
Factors Behind Changes in Business Performance

The company has not provided an explicit explanation of the factors behind the increase or decrease. On the income statement, research and development expenses were ¥1,536,525 thousand and selling, general and administrative expenses were ¥149,814 thousand, both down from the same period of the previous year. The company also recorded a gain on the sale of fixed assets of ¥17,439 thousand and a gain on collection of amortized receivables of ¥36,373 thousand.

Disclosure regarding the going concern assumption

The disclosure includes a description of material events and other matters. Although the company states that circumstances exist that raise significant doubt about the going concern assumption, it recognizes no material uncertainty regarding that assumption. The note on the going concern assumption states, "There are no applicable matters."

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name Not disclosed
Material subsequent eventsFrom 1 October 2026 through the end of October, the company issued 2,320,000 common shares through the exercise of stock acquisition rights, increasing share capital and capital surplus by ¥33,217 thousand each.
Impairment loss¥2,695 thousand
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥17,439 thousand, Gain on collection of written-off receivables ¥36,373 thousand / Extraordinary loss Impairment Losses ¥2,695 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNo (a financial results presentation video is scheduled to be released)
Issued Shares at Period-End113,634,098 shares
Treasury Shares at Period-End64 shares
Results for this period
ItemDetails
Fiscal Period ClassificationThird quarter
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 January 2026 to 30 September 2026
Operating profit¥-1,686 million
Ordinary income¥-1,650 million
Profit attributable to owners of the parent¥-1,608 million
Net income per share(¥16.59)
Equity ratioEnd of the current fiscal period 91.9 / End of previous period 93
Total assets¥2,459 million
Net assets¥2,317 million
Annual Dividend Forecast¥0 → ¥0(0.0%)
Impairment loss¥2,695 thousand
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥17,439 thousand, Gain on collection of written-off receivables ¥36,373 thousand / Extraordinary loss Impairment Losses ¥2,695 thousand
Disclosure regarding the going concern assumptionThe disclosure includes a description of material events and other matters. Although the company states that circumstances exist that raise significant doubt about the going concern assumption, it recognizes no material uncertainty regarding that assumption. The note on the going concern assumption states, "There are no applicable matters."
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name Not disclosed
Material subsequent eventsFrom 1 October 2026 through the end of October, the company issued 2,320,000 common shares through the exercise of stock acquisition rights, increasing share capital and capital surplus by ¥33,217 thousand each.
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNo (a financial results presentation video is scheduled to be released)
Issued Shares at Period-End113,634,098 shares
Treasury Shares at Period-End64 shares
Factors Behind Changes in Business PerformanceThe company has not provided an explicit explanation of the factors behind the increase or decrease. On the income statement, research and development expenses were ¥1,536,525 thousand and selling, general and administrative expenses were ¥149,814 thousand, both down from the same period of the previous year. The company also recorded a gain on the sale of fixed assets of ¥17,439 thousand and a gain on collection of amortized receivables of ¥36,373 thousand.
Items this document does not state (15)
Net SalesOperating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogDepreciation and amortization

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company has not specified the reasons for the year-on-year changes in profit and loss.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Q3 Financial Results for the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated) | Modalis Therapeutics Corporation (4883) timely disclosure | Komori